N-((8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methylbutanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methylbutanamide
• 英文别名: N-[(8-hydroxyquinolin-7-yl)(phenyl)methyl]-3-methylbutanamide；N-[(8-hydroxy-7-quinolyl)-phenyl-methyl]-3-methyl-butanamide；N-[(8-hydroxyquinolin-7-yl)-phenylmethyl]-3-methylbutanamide
• 化学式: C₂₁H₂₂N₂O₂
• 分子量: 334.418
• InChiKey: UECHRCZFFNFJCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  8-羟基喹啉 、 异戊酰胺 、 苯甲醛 反应 3.0h， 以64%的产率得到N-((8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methylbutanamide
  参考文献：
  名称：

  Betti reaction enables efficient synthesis of 8-hydroxyquinoline inhibitors of 2-oxoglutarate oxygenases

  摘要：

  使用Betti反应高效生成2OG氧化酶抑制剂，包括KDM4去甲基酶。

  DOI：

  10.1039/c5cc06095h

文献信息

• Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
  申请人：CORNELL UNIVERSITY

  公开号：US10716783B2

  公开（公告）日：2020-07-21

  Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.

  治疗神经细胞损伤患者的方法，该方法包括向患者施用有效量的具有下通式(1)的HIF脯氨酰-4-羟化酶抑制化合物 其中R1是含有至少三个至多七个碳原子的环状基团，任选含有一个或多个选自O、N和S的杂原子，并任选通过连接基团连接到所示碳原子；R2 独立地选自 R1 的环状基团和含有多达 20 个碳原子的无环烃基团 R5；R3 选自氢原子和含有多达 6 个碳原子的烃基团；R6 和 R7 独立地选自氢原子、含有多达 3 个碳原子的烃基团、卤素原子和极性基团及其亚甲基连接型；以及 t 为 0 或 1。
• QUINOLINE DERIVATIVES
  申请人：Envivo Pharmaceuticals, Inc.

  公开号：EP2079699A1

  公开（公告）日：2009-07-22
• PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY
  申请人：Cornell University

  公开号：EP3079697B1

  公开（公告）日：2021-02-03
• PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM
  申请人：CORNELL UNIVERSITY

  公开号：US20160317526A1

  公开（公告）日：2016-11-03

  Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R 1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R 2 is independently selected from said cyclic groups of R 1 and acyclic hydrocarbon groups R 5 containing up to twenty carbon atoms; R 3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R 6 and R 7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.
• [EN] QUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLINE
  申请人：CHRONOGEN INC

  公开号：WO2008014602A1

  公开（公告）日：2008-02-07

  [EN] The invention relates to new quinoline derivatives which are active CLK-1 inhibitors. More specifically, the CLK-1 inhibitors of the invention are compounds of formula (A). The invention also relates to pharmaceutical compositions comprising such compounds and to methods for the prophylaxis and/or treatment of disorders or their associated symptoms for which the inhibition of CLK-1 is beneficial.
  [FR] L'invention concerne de nouveaux dérivés de quinoline constituant des inhibiteurs actifs de CLK-1. Les inhibiteurs de CLK-1 de l'invention sont, plus spécifiquement, des composés représentés par la formule (A). L'invention concerne également des compositions pharmaceutiques contenant lesdits composés et des méthodes prophylactiques et/ou thérapeutiques de troubles ou des symptômes associés dans lesquels l'inhibition de CLK-1 est bénéfique.